New GLP-1 analogue wows major conference

A new GLP-1 analogue, semaglutide, significantly reduces the risk of CV death, non-fatal myocardial infarction or non-fatal stroke by 26% compared with placebo, a major trial has found.

The numbers of patients who need to be treated to prevent one cardiovascular-related event over 24 months was 45.

From a mean baseline of 8.7%, semaglutide cut HbA1c by 1.1% with an 0.5mg dose and by 1.4% with 1